Published 30-Day FRN

sradovich on DSK3TPTVN1PROD with NOTICES

Federal Register / Vol. 81, No. 103 / Friday, May 27, 2016 / Notices
passive), and novel adjuvants, including
the coordinated role that mucosal and
systemic immunity play in protection
from viral acquisition and infection.
2. Emerging topics related to the
development, testing, and formulation
of microbicides, pre-exposure
prophylaxis candidates, long acting/
and/or injectable formulations of
antiretroviral treatment candidates (and
related methods of delivery for HIV
treatments) that are less toxic, longer
acting, have fewer side effects and
complications, and easier to take and
adhere to than current regimens.
3. Emerging topics that relate to the
research toward a cure, including the
development of novel approaches and
strategies that could lead to sustained
HIV remission or viral eradication
without the continuing need for
combination antiretroviral therapy,
including studies of HIV persistence,
latency, and reservoir formation.
4. Emerging topics that relate to the
HIV cascade of care, including the
development, testing, and
implementation of integrated
biomedical, behavioral, and social
science strategies to improve HIV testing
and entry into prevention and treatment
services, including linkage, engagement,
and retention in these services for
optimal treatment response.
5. Emerging topics that relate to basic
research underlying the basic biology of
HIV, (e.g., acquisition, transmission and
pathogenesis; viral persistence; immune
dysfunction and chronic inflammation;
host microbiome and genetic
determinants; and pathogenesis of
opportunistic infections, coinfections,
comorbidities, and HIV-related
mortalities.
6. Emerging topics that relate to
reducing health disparities in the
incidence of new HIV infections or in
treatment outcomes of those living with
HIV/AIDS, with a specific focus on
structural, environmental, and
community-level determinants of health
and the interplay of these determinants
in developing strategies to mitigate the
disparities in HIV incidence and access
to HIV preventive and treatment
services,
7. Emerging topics that relate to the
challenges and opportunities that
should be considered for research
training and career development
programs targeting researchers
conducting high priority HIV/AIDS
research.

VerDate Sep<11>2014

18:00 May 26, 2016

Jkt 238001

Please limit responses to <1500
characters. Responses to this RFI Notice
are voluntary. The submitted
information will be reviewed by NIH
staff and may be made available to the
public. Submitted information will not
be considered confidential. This request
is for information and planning
purposes and should not be construed
as a solicitation or as an obligation of
the federal government or the NIH. No
awards will be made based on responses
to this Request for Information. The
information submitted will be analyzed
and may be used in reports or
presentations. Those who respond are
advised that the NIH is under no
obligation to acknowledge receipt of
your comments, or provide comments
on your submission. No proprietary,
classified, confidential and/or sensitive
information should be included in your
response. The NIH and the government
reserve the right to use any nonproprietary technical information in any
future solicitation(s).
Dated: May 20, 2016.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2016–12578 Filed 5–26–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; The Clinical Trials
Reporting Program (CTRP) Database
(NCI)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Cancer Institute (NCI), the National
Institutes of Health, has submitted to the
Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on March 11, 2016
(Vol. 81, P. 12914) and allowed 60-days
for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an

SUMMARY:

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

33681

information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
To
obtain a copy of the data collection
plans and instruments, or request more
information on the proposed project,
contact: Jose Galvez, MD, Office of the
Director, National Cancer Institute, 9609
Medical Center Drive, Rockville, MD
20852 or call non-toll-free number 240–
276–5206 or Email your request,
including your address to: jose.galvez@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
Proposed Collection: The Clinical
Trials Reporting Program (CTRP)
Database (NCI), 0925–0600, Expiration
Date 05/31/2016—Revision, National
Cancer Institute (NCI), National
Institutes of Health (NIH).
Need and Use of Information
Collection: The Clinical Trials Reporting
Program (CTRP) is an electronic
resource that serves as a single,
definitive source of information about
all NCI-supported clinical research. This
resource allows the NCI to consolidate
reporting, aggregate information and
reduce redundant submissions.
Information is submitted by clinical
research administrators as designees of
clinical investigators who conduct NCIsupported clinical research. The
designees can electronically access the
CTRP Web site to complete the initial
trial registration. Subsequent to
registration, four amendments and four
study subject accrual updates occur per
trial annually.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The estimated
annualized burden hours are 18,000.

FOR FURTHER INFORMATION CONTACT:

E:\FR\FM\27MYN1.SGM

27MYN1

33682

Federal Register / Vol. 81, No. 103 / Friday, May 27, 2016 / Notices

sradovich on DSK3TPTVN1PROD with NOTICES

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Average
time per
response
(in hours)

Number of
responses per
respondent

Total annual
burden
hours

Type of respondents

Form

Clinical Trials .....................................

Initial Registration .............................
Amendment ......................................
Update ..............................................
Accrual Updates ...............................

3,000
1,500
1,500
3,000

1
4
4
4

1
1
1
15/60

3,000
6,000
6,000
3000

Total ...........................................

...........................................................

9,000

27,000

........................

18,000

Dated: May 20, 2016.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, NIH.

Dated: May 23, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2016–12504 Filed 5–26–16; 8:45 am]

[FR Doc. 2016–12502 Filed 5–26–16; 8:45 am]

BILLING CODE 4140–01–P

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institutes of Health

National Heart, Lung, and Blood
Institute; Notice of Closed Meeting

Center for Scientific Review; Notice of
Closed Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Grant Review for NHLBI K Award Recipients.
Date: June 21, 2016.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Melissa E Nagelin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7202, Bethesda, MD 20892, 301–435–0297,
nagelinmh2@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)

Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neuroimaging, Neuroinformatics
and Neurogenetics.
Date: June 10, 2016.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Vilen A. Movsesyan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040M,
MSC 7806, Bethesda, MD 20892, 301–402–
7278, movsesyanv@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–14–

VerDate Sep<11>2014

18:00 May 26, 2016

Jkt 238001

PO 00000

Frm 00029

Fmt 4703

Sfmt 4703

166: Early Phase Clinical Trials in Imaging
and Image-Guided Interventions.
Date: June 17, 2016.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Chiayeng Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Room 5213, MSC 7852, Bethesda, MD 20892,
301–435–2397, chiayeng.wang@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: HIV/AIDS Innovative Research
Applications.
Date: June 21–22, 2016.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
Bethesda, MD 20892, 301–451–8754, tuoj@
nei.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Clinical and
Translational Imaging Applications.
Date: June 22, 2016.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Eileen W. Bradley, DSC,
Chief, SBIB IRG, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5100, MSC 7854, Bethesda, MD
20892, (301) 435–1179, bradleye@csr.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Drug Discovery and Mechanisms of
Antimicrobial Resistance Study Section.
Date: June 23–24, 2016.
Time: 8:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: American Inn of Bethesda, 8130
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Guangyong Ji, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3188,
MSC 7808, Bethesda, MD 20892, 301–435–
1146, jig@csr.nih.gov.

E:\FR\FM\27MYN1.SGM

27MYN1